ARTICLE | Company News
Galenea in-licenses 5-HT2C agonists
October 29, 2008 1:16 AM UTC
Galenea ( Cambridge, Mass.) received exclusive, worldwide rights to develop and commercialize selective serotonin (5-HT2C) receptor agonists from Organix (Woburn, Mass.), Case Western Reserve Universi...